Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 2, Issue 11, 1996, Pages 1811-1818

  Meredith, Ruby F ^a   Khazaeli, M B ^b   Plott, Walter E ^a   Grizzle, William E ^c   Liu, Tiepu ^b   Schlom, Jeffrey ^e   Russell, Charles D ^d   Wheeler, Richard H ^b   LoBuglio, Albert F ^b  

^a The University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CARCINOEMBRYONIC ANTIBODY; IODINE 123; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; TAG 72 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERONS; INTERLEUKIN-1; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0029835449     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Muraro. R., Wunderlich, D , Thor, A., Lundy, J., Noguchi, P., Cunningham, R., and Schlom, J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res., 45: 5769-5780, 1985.
2. Colcher, D., Hand, P. H.., Nuti, M., and Schlom, J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA, 78: 3199-3203, 1981.
3. Johnson, V. G., Schlom, J., Paterson, A. J., Bennett. J., Magnani, J. L., and Colcher, D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res., 46: 850-857, 1986.
4. Simpson, J. F., Primus, F. J., and Schlom, J. Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas. Intl. J. Biol. Markers, 6: 83-90, 1991.
5. Blumenthal, R. D., Kashi, R , Stephens, R., Sharkey, R. M., and Goldenberg, D. M. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol. Immunother., 32: 303-310, 1991.
6. Sung, C., Shockley, T. R., Morrison, P. F., Dvorak, H. F., Yarmush, M. L., and Dedrick, R. L. Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res., 52: 377-384, 1992.
7. Guadagni, F., Schlom, J., Johnston, W. W., Szpak, C. A., Goldstein, D., Smalley, R., Simpson, J. F., Borden, E. C., Pestka, S., and Greiner, J. W. Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells. J. Natl. Cancer Inst., 81: 502-512, 1989.
8. Greiner, J. W , Hand, P. H., Noguchi, P., Fisher, P. B., Pestka, S , and Schlom, J. Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte α-interferon treatment. Cancer Res., 44: 3208-3214, 1984.
9. Schlom, J., Hand, P. H., Greiner, J. W., Colcher, D., Shrivastav, S., Carrasquillo, J. A., Reynolds, J. C., Larson, S M., and Raubitschek, A. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res., 50 (Suppl.): 820s-827s, 1990
10. Yan, X. W., Wong, J. Y., Esteban, J. M., Kuhn, J. A., Beatty, B. G., Beatty, J. D., and Shively, J. E. Effects of recombinant human γ-interferon on carcinoembryonic antigen expression of human colon cancer cells J. Immunother., 11: 77-84, 1992.
11. 131I-CC49) when given in combination with γ-interferon. Cancer Res., 53: 600-608, 1993.
12. Greiner, J. W., Guadagni, F, Goldstein, D., Borden, E. C., Ritts, R. E., Jr., Witt, P., LoBuglio, A. F., Saleh, M. N., and Schlom, J. Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons Cancer Res., 51: 4155-4163, 1991.
13. Greiner, J. W., Smalley, R. V., Borden, E. C., Martin, E. W., Guadagni, F., Roselli, M., and Schlom, J. Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas. J. Surg. Oncol., 2 (Suppl.): 9-13, 1991.
14. 131I-CC49 Mab plus α interferon (rIFNα) in breast cancer. J. Immunother., 16: 162, 1994.
15. Meredith, R. F., Bueschen, A. J., Khazaeli, M. B., Plott, W. E., Grizzle, W. E., Wheeler, R. H., Schlom, J., Russell. C. D., Liu, T., and LoBuglio, A. F. Treatment of metastatic prostate cancer with radiolabeled antibody CC49. J. Nucl. Med., 35: 1017-1022, 1994.
16. 131I-CC49 in colorectal cancer. Cancer (Phila.), 73 (Suppl.): 1057-1066, 1994
17. Divgi, C. R., Scott, A. M., Dantis, L., Capitelli, P., Siler, K., Hilton, S., Finn, R. D., Kemeny, N., Kelsen, D., and Kostakoglu, L. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J. Nucl. Med., 36: 586-592, 1995.
18. Wheeler, R. H., Meredith, R. F., Saleh, M. N., Khazaeli, M. B., Murray, J. L., and LoBuglio, A. F. A phase II trial of IL-1 + radioimmunotherapy (RIT) in patients (pts) with metastatic colon cancer. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 13: 295, 1994.
19. Myers, R. B., Meredith, R. F., Schlom, J., LoBuglio, A F., Bueschen, A. J., Wheeler, R. H., Stockard, C, R., and Grizzle, W. E. Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. J. Urol., 152: 243-246, 1994.
20. Greiner, J. W., Guadagni, F , Goldstein, D., Smalley, R. V., Borden, E. C., Simpson, J. F., Molinolo, A., and Schlom, J. Iniraperitoneal administration of interferon-γ to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J. Clin. Oncol., 10: 735-746, 1992.
21. 111In-labeled and antimelanoma antibody 96.5 in melanoma patients. J. Natl. Cancer Inst., 80: 160-165, 1988.
22. Yu, B., Carrasquillo, J., Milenic, D., Chung, Y., Perentesis, P., Feuerestein, I., Eggensperger, D., Qi, C-F., Paik, C., Reynolds, J., Grem, J., Curt, G., Siler, K., Schlom, J., and Allegra, C. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J. Clin. Oncol., 14: 1798-1809. 1996.
23. Meredith, R. F., LoBuglio, A. F., Plott, W. E., Orr, R A., Brezovich, I. A., Russell, C. D., Harvey, E. B., Yester, M. V., Wagner, A. J., Spencer, S. A., Wheeler, R. H., Saleh, M. N., Rogers, K. J., Polansky, A., Salter, M. M., and Khazaeli, M. B. Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,K 17-1A monoclonal antibody. J. Nucl Med., 32: 1162-1168, 1991.
24. Loevinger, R., and Berman, M. A revised schema for calculating the absorbed dose from biologically distributed radionuclides, MIRD Pamphlet No 1. New York: Society of Nuclear Medicine, 1976.
25. Snyder, W. S., Ford, M R., Warner, G. G., and Watson, S. B. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11. New York: Society of Nuclear Medicine, 1975.
26. Dillman, L. T., and Von Der Lage, F. C. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation, MIRD Pamphlet No. 10. New York: Society of Nuclear Medicine, 1975.
27. Ellett, W. H., and Humes, R. M. Absorbed fractions for small volumes containing photon emitting radioactivity, MIRD Pamphlet No. 8. New York: Society of Nuclear Medicine, 1971.
28. Sgouros, G Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med., 34: 689-694, 1993.
29. Coffey, J. L., and Watson, E. E. Calculating dose from remaining body activity: a comparison of two methods. Med Phys., 6: 307-308, 1979
30. Snyder, W. S., Ford, M. R., and Warner, G. G. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom, MIRD Pamphlet No.5. New York: Society of Nuclear Medicine, 1978.
31. 131I-labeled anticarcinoembryonic antigen monoclonal antibody. Cancer Res., 50 (Suppl.): 1039s-1042s, 1990.
32. Thomas, S. R., Maxon, H. R., and Kereiakes, J. G. In vivo quantitation of lesion radioactivity using external counting methods. Med. Phys., 3: 253-255, 1976.
33. Begent, R. H., Ledermann, J. A., Green, A. J., Bagshawe, K. D., Riggs, S. J., Searle, F., Keep, P. A., Adam, T., Dale, R. G., and Glaser, M. G. Antibody distribution and dosimetry in patients receiving radiolabeled antibody therapy for colorectal cancer. Br. J. Cancer, 60: 406-412, 1989.
34. Muraro, R., Kuroki, M., Wunderlich, D., Poolc, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., and Noguchi, P. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res., 48: 4588-4596, 1988.
35. Kuroki, M., Greiner, J, W., Simpson, J. F., Primus, F. J., Guadagni, F., and Schlom, J. Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. Int. J. Cancer, 44: 208-218, 1989.
36. LoBuglio, A. F., Wheeler, T. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B , Sun, L., Ghrayeb, J., and Khazaeli, M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA, 86: 4220-4224, 1989.
37. Labaune, J. P. Handbook of Pharmacokinetics, Toxicity Assessment of Chemicals. New York: John Wiley & Sons, 1989.
38. Snedecor, G. W., and Cochran, W. G. Statistical Methods, Ed. 7, pp. 191-193. Ames, IA: The Iowa State University Press, 1980.
39. Abdel-Nabi, H., and Doerr, R. J. Localization of colorectal carcinoma with a combination of In-111 CYT-103 and In-111 CYT-372 monoclonal antibodies. J. Nucl. Med., 35: 11, 1994.
40. Kemshead, J T., Papanastassiou, V., Coakham, H. B., and Pizer, B. L Monoclonal antibodies in the treatment of central nervous system malignancies. Eur. J. Cancer, 28: 511-513, 1992.
41. Buist, M. R., Kenemans, P., Molthoff, C. F., Roos, J. C., den Hollander. W., Brinkhuis, M., and Baak, J P. Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics. Int. J. Cancer, 64: 92-98, 1995.